Aspirin and Preeclampsia

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Preeclampsia Postpartum

In brief

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Key facts

Study ID

NCT04479072

Run by

University of Chicago

People needed

180

Starts

2021-02-15

Expected to finish

2026-12-31

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pregnant Adults between 18 and 45 years of age
• Diagnosed with preeclampsia
• Presenting for delivery with a singleton gestation.

You may not qualify if…

• We will exclude patients in labor
• Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
• Plan to deliver outside of the participating site
• Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
• Aspirin allergy
• Clear indication for aspirin therapy or contraindication to aspirin therapy
• Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
• Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
• Those who cannot provide consent

Where it is running

• University of Chicago Hospital — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.